Mural Oncology plc
MURANASDAQHealthcare
$2.04
+$0.00(+0.00%)
Market Cap$35382751
P/E Ratio—
52W High$4.74
52W Low$0.95
Mural Oncology plc (MURA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MURA · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2025Report Date: Nov 6, 2025EPS Actual
-$0.21
Est. -$0.59 · +64.4%
Revenue
—
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Nov 6, 2025
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
MURA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.59 | -$0.21 | +64.4% | — | — | — |
| ▼ Q3 FY2025 | Aug 4, 2025 | -$1.13 | -$1.77 | -56.6% | — | — | — |
| ▲ Q2 FY2025 | May 14, 2025 | -$2.12 | -$1.93 | +9.0% | — | — | — |
| ▼ Q1 FY2025 | Mar 11, 2025 | -$1.98 | -$2.01 | -1.5% | $0.00B | — | — |
| ▲ Q4 FY2024 | Nov 13, 2024 | -$1.96 | -$1.87 | +4.6% | — | — | — |
| ▲ Q3 FY2024 | Aug 13, 2024 | -$1.90 | -$1.86 | +2.1% | — | — | — |
| ▲ Q2 FY2024 | May 14, 2024 | -$2.66 | -$1.84 | +30.8% | — | — | — |
| — Q1 FY2024 | Mar 26, 2024 | — | -$3.57 | — | $0.00B | — | — |
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.21
EPS Est.
-$0.59
EPS Surpr.
+64.4%
Revenue
—
Q3 FY2025
Aug 4, 2025Miss
EPS Actual
-$1.77
EPS Est.
-$1.13
EPS Surpr.
-56.6%
Revenue
—
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$1.93
EPS Est.
-$2.12
EPS Surpr.
+9.0%
Revenue
—
Q1 FY2025
Mar 11, 2025Miss
EPS Actual
-$2.01
EPS Est.
-$1.98
EPS Surpr.
-1.5%
Revenue
$0.00B
Q4 FY2024
Nov 13, 2024Beat
EPS Actual
-$1.87
EPS Est.
-$1.96
EPS Surpr.
+4.6%
Revenue
—
Q3 FY2024
Aug 13, 2024Beat
EPS Actual
-$1.86
EPS Est.
-$1.90
EPS Surpr.
+2.1%
Revenue
—
Q2 FY2024
May 14, 2024Beat
EPS Actual
-$1.84
EPS Est.
-$2.66
EPS Surpr.
+30.8%
Revenue
—
Q1 FY2024
Mar 26, 2024
EPS Actual
-$3.57
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.74 | $-0.74 | $-0.74 | 1 |
| Q3 FY2027 | $-0.74 | $-0.74 | $-0.74 | 1 |
| Q2 FY2027 | $-0.75 | $-0.75 | $-0.75 | 1 |
| Q1 FY2027 | $-0.75 | $-0.75 | $-0.75 | 1 |
| Q4 FY2026 | $-0.77 | $-0.77 | $-0.77 | 1 |
| Q3 FY2026 | $-0.88 | $-0.88 | $-0.88 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $-0.0B | $-0.0B | $-0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q4 FY2025 | Nov 6, 2025 | +64.4% | $2.08 | $2.09 | +0.48% |
| ▼ Q3 FY2025 | Aug 4, 2025 | -56.6% | $2.32 | $1.85 | -20.26% |
| ▲ Q2 FY2025 | May 14, 2025 | +9.0% | $2.66 | $2.56 | -3.76% |
| ▼ Q1 FY2025 | Mar 11, 2025 | -1.5% | $3.63 | $3.80 | +4.68% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +4.6% | $3.52 | $3.52 | +0.00% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +2.1% | $3.14 | $3.11 | -0.96% |
| ▲ Q2 FY2024 | May 14, 2024 | +30.8% | $3.75 | $3.92 | +4.53% |
| — Q1 FY2024 | Mar 26, 2024 | — | $4.32 | $4.49 | +3.94% |
Q4 FY2025+0.48%
Report Date
Nov 6, 2025
EPS Beat/Miss
+64.4%
Price Before
$2.08
Price After
$2.09
Q3 FY2025-20.26%
Report Date
Aug 4, 2025
EPS Beat/Miss
-56.6%
Price Before
$2.32
Price After
$1.85
Q2 FY2025-3.76%
Report Date
May 14, 2025
EPS Beat/Miss
+9.0%
Price Before
$2.66
Price After
$2.56
Q1 FY2025+4.68%
Report Date
Mar 11, 2025
EPS Beat/Miss
-1.5%
Price Before
$3.63
Price After
$3.80
Q4 FY2024+0.00%
Report Date
Nov 13, 2024
EPS Beat/Miss
+4.6%
Price Before
$3.52
Price After
$3.52
Q3 FY2024-0.96%
Report Date
Aug 13, 2024
EPS Beat/Miss
+2.1%
Price Before
$3.14
Price After
$3.11
Q2 FY2024+4.53%
Report Date
May 14, 2024
EPS Beat/Miss
+30.8%
Price Before
$3.75
Price After
$3.92
Q1 FY2024+3.94%
Report Date
Mar 26, 2024
EPS Beat/Miss
—
Price Before
$4.32
Price After
$4.49
Avg Beat Reaction+0.06%
Avg Miss Reaction-7.79%
Beat Rate5 / 8 quarters
Largest Move-20.26% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MURA ends December
Mural Oncology plc (MURA) most recently reported earnings on November 6, 2025 for Q4 FY2025, posting EPS of $-0.21 — beating the analyst consensus of $-0.59 by +64.4%. The next MURA earnings date is expected around September 1, 2026.
Each quarter, investors track MURA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MURA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MURA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MURA earnings · 5 questionsMural Oncology plc's next earnings report is expected around September 1, 2026. MURA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MURA historically reports after market close (AMC).
MURA earnings datewhen is MURA earningsMURA next earnings datewhen does MURA report earningsMURA earnings calendar
▸ Source: FMP · Mural Oncology plc SEC filings · US GAAP · Mural Oncology plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026